Washington, DC - Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Impax Laboratories Inc.’s acquisition of  CorePharma, LLC would likely be anticompetitive.

Under the order, first announced in March 2015, the pharmaceutical companies have agreed to divest CorePharma’s rights and assets to generic pilocarpine tablets, which are used to treat dry mouth, and generic ursodiol tablets, which are used to treat biliary cirrhosis and gall bladder diseases. Perrigo Company plc, a global drug company headquartered in Ireland that markets generic drugs in the United States, is the Commission-approved  buyer of the divested assets.

The Commission vote approving the final order was 5-0. (FTC File No. 151 0011; the staff contact is Christina R. Perez, Bureau of Competition, 202-326- 2048)